RenoFi | $22,000,000 | (Mar 4, 2026)
Worldscape | Undisclosed Amount | (Mar 4, 2026)
MightyFly | $10,000,000 | (Mar 4, 2026)
Vitarka Therapeutics
United Kingdom
- London
- 12/04/2023
- Unknown
- $1,580,000
Curing the untreated: Vitarka Therapeutics is a pre-clinical biotech company determined to combat late-stage cancers.
- Industry Biotechnology Research
- Website https://www.vitarka.co.uk/
- LinkedIn https://www.linkedin.com/company/vitarka-therapeutics/
Related People
Vineeta TripathiFounder
United Kingdom -
London, England
15+ years’ in Pharmaceutical drug development for biologics within Neuroscience, Immuno-Oncology and Ophthalmology, project management, target product profile, go-to market strategy. Co-founded Vitarka Therapeutics, currently fundraising Seed investment round. Academic expertise in discovery and validation of TDP-43 mutations causing Motor Neuron Disease. Proven track record of publications in journals such as Science and Nature; total citation score of >7000. Co-inventor on patents for chimeric neurotoxin NMEs and therapeutic antibodies. Delivered 2 candidates to clinic for wet AMD. Won 3rd place for the 1st Roche pRED Oncology Award for innovative scientific achievements in “Novel highly tumor-selective membrane targets for antibody-based cancer therapy”.
Qura | $1,739,595 | (Mar 4, 2026)
KeyCare | $27,400,000 | (Mar 4, 2026)
Devotion(US) | $4,000,000 | (Mar 4, 2026)
Burst | $2,100,000 | (Mar 4, 2026)
JetStream Security Inc. | $34,000,000 | (Mar 4, 2026)
Escargot | $2,750,000 | (Mar 4, 2026)
EGI Battery | $10,000,000 | (Mar 4, 2026)
Bindbridge | $3,800,000 | (Mar 4, 2026)
Inhouse | $5,000,000 | (Mar 3, 2026)